Business Roundtable
M&A/Dealmaking: Full-Steam Ahead - The Evolving Biotech M&A Market
Wednesday, February 15, 2006
3:30 PM
Conrad Suite
Life-science M&A activity in 2005 proved to be a sprint to the finish with the announcement of multiple deals right up to the last days in December, including the $2.2 billion acquisition of Abgenix by Amgen and OSI?s acquisition of Eyetech. It has been forecast that M&A trends favor continued consolidation in the biotech group. Will 2006 be another blockbuster year of biotech mega-deals? This roundtable discussion will take a peek behind the scenes of the deal-making process and look at the developing trends in the evolving biotech M&A market.
Moderators
- John Dwyer; Counsel, Arent Fox LLP
Panelists
- Arthur J. Klausner, MBA; Partner, Pappas Ventures
- Roger Longman; Managing Partner, Windhover Information Inc.
- Barbara Yanni; Vice President and Chief Licensing Officer, Merck & Co.
- Stephen H. Sands; Managing Director, Lazard Frères & Co. LLC
- Stephen Potter; Vice President, Corporate Development, Genzyme Corporation